Medical device innovation: Signatera
Natera
Natera’s Signatera is a molecular residual disease assay (MRD) that identifies cancer relapse earlier than standard-of-care tools.
Natera designed Signatera as a tumor-specific assay for individualized cancer care. It has a custom-built assay that is based on the unique mutation signature of a tumor and can identify and track tumor mutations at the source.
Once the system personalizes the assay, a patient’s blood can be used to accurately monitor for cancer over time. It is used after surgery to evaluate the need for adjuvant chemotherapy.
Next >>